Disease relevance of Platelet Function Tests

• The antithrombotic effect of thromboxane receptor antagonist HN 11500 on thrombus formation in laser thrombosis model and platelet function tests [1].

High impact information on Platelet Function Tests

• Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug [2].
• MEASUREMENTS AND MAIN RESULTS--Blood was taken for platelet function tests, PGI2 metabolite assay, and red cell deformability before and 2 h after the trial dose was taken [3].
• Platelet function tests were performed on one patient during the initial therapy and after rechallenge with nafcillin [4].
• There is considerable evidence that the quantity or quality of plasma lipids influences platelet function tests, and clofibrate reduces high plasma lipids and alters some platelet tests [5].
• Neither the fish oil nor the placebo group had significant changes in vital signs or platelet function tests (bleeding time, thromboxane B2, platelet factor 4 and beta-thromboglobulin) during the study [6].

Chemical compound and disease context of Platelet Function Tests

• The effect of thromboxane receptor antagonist HN 11500 (Chemie Linz AG, Austria) on thrombus formation in laser thrombosis model and platelet function test has been studied [1].

Biological context of Platelet Function Tests

• Prothrombin time, activated partial thromboplastin time, platelet count, and platelet function test results were measured before heparinization, after protamine administration, and then every 2 hours [7].
• Routine coagulation tests (platelet count, activated partial thromboplastin time, prothrombin time, antithrombin III activity) and platelet function tests (whole blood aggregometry, thrombelastography, flow cytometry) were performed [8].
• Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition [9].
• Platelet aggregation induced by stirring of a platelet suspension after activation by the exogenous addition of stimulants, such as ADP, epinephrine and thrombin, has long been used as a platelet function test, and for the screening of antiplatelet agents [10].

Associations of Platelet Function Tests with chemical compounds

• The effect of dihydroergotamine on various platelet function tests and venous prostacyclin-formation in men [11].
• In relation to their lower activity, platelets from group II exhibited a significant increase in 22:4n-6 (phospholipids) and in the ratio cholesterol/phospholipids, both significantly correlated with the platelet function tests [12].
• Platelet function tests during major operation for gastro-intestinal carcinoma [13].
• The abnormal platelet function tests and biochemical abnormalities (decreased values of platelet total adenosine diphosphate (ADP), adenosine triphosphate (ATP(I) and serotonin) remained unchanged [14].
• Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives [15].

Gene context of Platelet Function Tests

• Platelet function tests could not detect any alteration of in vivo platelet activity in terms of platelet aggregate formation or plasma concentrations of PF4 and beta-TG [16].
• No difference could be demonstrated between either platelet function tests or serum level of von Willebrand factor antigen during treatment with CSII and MII [17].
• In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests [18].
• We have developed a new platelet function test which is a method to estimate the rate of release of aldolase from platelets into a low osmotic pressured artificial medium and into PRP, which we called the platelet aldolase release rate [19].

References